123 related articles for article (PubMed ID: 34203430)
1. Cholesterol: Enhancing FGF2 translocation in unconventional secretion.
Wang H; Zhang M; Ge L
J Cell Biol; 2022 Nov; 221(11):. PubMed ID: 36255389
[TBL] [Abstract][Full Text] [Related]
2. Cholesterol promotes clustering of PI(4,5)P2 driving unconventional secretion of FGF2.
Lolicato F; Saleppico R; Griffo A; Meyer A; Scollo F; Pokrandt B; Müller HM; Ewers H; Hähl H; Fleury JB; Seemann R; Hof M; Brügger B; Jacobs K; Vattulainen I; Nickel W
J Cell Biol; 2022 Nov; 221(11):. PubMed ID: 36173379
[TBL] [Abstract][Full Text] [Related]
3. FGF2 Is Protective Towards Cisplatin-Induced KGN Cell Toxicity by Promoting FTO Expression and Autophagy.
Wang R; Wang L; Wang L; Cui Z; Cheng F; Wang W; Yang X
Front Endocrinol (Lausanne); 2022; 13():890623. PubMed ID: 35784556
[TBL] [Abstract][Full Text] [Related]
4. Tubular cells produce FGF2 via autophagy after acute kidney injury leading to fibroblast activation and renal fibrosis.
Livingston MJ; Shu S; Fan Y; Li Z; Jiao Q; Yin XM; Venkatachalam MA; Dong Z
Autophagy; 2023 Jan; 19(1):256-277. PubMed ID: 35491858
[TBL] [Abstract][Full Text] [Related]
5. FGF2 is an endogenous regulator of alcohol reward and consumption.
Even-Chen O; Herburg L; Kefalakes E; Urshansky N; Grothe C; Barak S
Addict Biol; 2022 Mar; 27(2):e13115. PubMed ID: 34796591
[TBL] [Abstract][Full Text] [Related]
6. FGF2 positively regulates osteoclastogenesis via activating the ERK-CREB pathway.
Wen X; Hu G; Xiao X; Zhang X; Zhang Q; Guo H; Li X; Liu Q; Li H
Arch Biochem Biophys; 2022 Sep; 727():109348. PubMed ID: 35835230
[TBL] [Abstract][Full Text] [Related]
7. Chronic exposure to FGF2 converts iPSCs into cancer stem cells with an enhanced integrin/focal adhesion/PI3K/AKT axis.
Sheta M; Hassan G; Afify SM; Monzur S; Kumon K; Abu Quora HA; Farahat M; Zahra MH; Fu X; Seno A; Seno M
Cancer Lett; 2021 Aug; 521():142-154. PubMed ID: 34455015
[TBL] [Abstract][Full Text] [Related]
8. Implications of different cell death patterns for prognosis and immunity in lung adenocarcinoma.
Zhou Y; Gao W; Xu Y; Wang J; Wang X; Shan L; Du L; Sun Q; Li H; Liu F
NPJ Precis Oncol; 2023 Nov; 7(1):121. PubMed ID: 37968457
[TBL] [Abstract][Full Text] [Related]
9. A Network Comprised of miR-15b and miR-29a Is Involved in Vascular Endothelial Growth Factor Pathway Regulation in Thymus Adipose Tissue from Elderly Ischemic Cardiomyopathy Subjects.
Gentile AM; Lhamyani S; Mengual Mesa M; Pavón-Morón FJ; Pearson JR; Salas J; Clemente-Postigo M; Pérez Costillas L; Fuster GO; El Bekay Rizky R
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833902
[TBL] [Abstract][Full Text] [Related]
10. Rethinking the potential and necessity of drug delivery systems in neovascular age-related macular degeneration therapy.
Huang X; Zhang L; Fu Y; Zhang M; Yang Q; Peng J
Front Bioeng Biotechnol; 2023; 11():1199922. PubMed ID: 37288355
[TBL] [Abstract][Full Text] [Related]
11. Aptamer Technology and Its Applications in Bone Diseases.
Liu X; Hu J; Ning Y; Xu H; Cai H; Yang A; Shi Z; Li Z
Cell Transplant; 2023; 32():9636897221144949. PubMed ID: 36591965
[TBL] [Abstract][Full Text] [Related]
12. Current status of cancer starvation therapy.
Li J; Tong D; Lin J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):241-250. PubMed ID: 35462463
[TBL] [Abstract][Full Text] [Related]
13. New developments in the biology of fibroblast growth factors.
Ornitz DM; Itoh N
WIREs Mech Dis; 2022 Jul; 14(4):e1549. PubMed ID: 35142107
[TBL] [Abstract][Full Text] [Related]
14. Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer.
Nakamura Y
Cells; 2021 Jun; 10(7):. PubMed ID: 34203430
[TBL] [Abstract][Full Text] [Related]
15. The FGF2 aptamer inhibits the growth of FGF2-FGFR pathway driven lung cancer cells.
Hamamoto J; Yasuda H; Nonaka Y; Fujiwara M; Nakamura Y; Soejima K; Betsuyaku T
Biochem Biophys Res Commun; 2018 Sep; 503(3):1330-1334. PubMed ID: 30005872
[TBL] [Abstract][Full Text] [Related]
16. Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease.
Matsuda Y; Nonaka Y; Futakawa S; Imai H; Akita K; Nishihata T; Fujiwara M; Ali Y; Bhisitkul RB; Nakamura Y
Mol Ther Nucleic Acids; 2019 Sep; 17():819-828. PubMed ID: 31454678
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology.
Cao J; Zhang F; Xiong W
Int J Nanomedicine; 2023; 18():4421-4430. PubMed ID: 37551274
[TBL] [Abstract][Full Text] [Related]
18. Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain.
Jin L; Nonaka Y; Miyakawa S; Fujiwara M; Nakamura Y
Mol Ther; 2016 Nov; 24(11):1974-1986. PubMed ID: 27506449
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
